← FDA DRUG APPROVALS

FDA ANDA · ANDA207252

DOCETAXEL

Sponsor: HENGRUI PHARMA

APPLICATION
ANDA207252
TYPE
ANDA
ORIGINAL APPROVAL
2017-08-09
LATEST ACTION
2023-09-19
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DOCETAXELPrescription
DOCETAXEL 160MG/8ML (20MG/ML) · INJECTABLE · INJECTION
DOCETAXELPrescription
DOCETAXEL 20MG/ML (20MG/ML) · INJECTABLE · INJECTION
DOCETAXELPrescription
DOCETAXEL 80MG/4ML (20MG/ML) · INJECTABLE · INJECTION

Approval history

2023-09-19Labeling · Supplement 10 · standardAP
2023-09-19Labeling · Supplement 9 · standardAP
2023-09-19Labeling · Supplement 7 · standardAP
2023-09-19Labeling · Supplement 5 · standardAP
2023-09-19Labeling · Supplement 3 · standardAP
2023-09-19Labeling · Supplement 6 · standardAP
2017-08-09UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →